XML 43 R34.htm IDEA: XBRL DOCUMENT
v3.23.2

MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - Revenues Recognized under Agreement (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended
--- | --- | ---
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022
Revenue related to Sanofi agreement: |  |  |  |
Revenues | $ 6,835 | $ 29,378 | $ 164,792 | $ 57,609
Novartis Institutes for BioMedical Research, Inc. |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues | 2,426 | 10,928 | 12,181 | 19,823
Novartis Institutes for BioMedical Research, Inc. | License and Service |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues | 1,872 | 8,622 | 9,568 | 15,640
Novartis Institutes for BioMedical Research, Inc. | Research services |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues | 554 | 2,306 | 2,613 | 4,183
Biogen MA, Inc. |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues | 2,204 | 10,052 | 134,506 | 21,245
Biogen MA, Inc. | License and Service |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues |  |  | 132,165 | 14,612
Biogen MA, Inc. | License |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues | 1,535 | 7,306 |  |
Biogen MA, Inc. | Research services |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues | 669 | 2,746 | 2,341 | 6,633
Kite Pharma, Inc. |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues | 1,231 | 6,334 | 13,539 | 12,642
Kite Pharma, Inc. | License and Service |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues |  |  | 12,550 | 12,386
Kite Pharma, Inc. | License |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues | 1,110 | 6,227 |  |
Kite Pharma, Inc. | Research services |  |  |  |
Revenue related to Sanofi agreement: |  |  |  |
Revenues | $ 121 | $ 107 | $ 989 | $ 256

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenuesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_NovartisInstitutesForBioMedicalResearchIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseAndServiceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=sgmo_ResearchServicesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_BiogenMAIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_LicenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=sgmo_KitePharmaIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |